What is the global market size of Macular Degeneration Treatment Market?

Macular Degeneration Treatment Market size was valued at USD 14.20 billion in 2021 and is poised to grow from USD 15.41 billion in 2022 to USD 29.59 billion by 2030, growing at a CAGR of 8.5% during the forecast period (2023-2030).

Macular Degeneration Treatment Market Updates

Macular Degeneration Treatment Market News

In November 2022, IVERIC bio, Inc. initiated the submission process for the first part of its New Drug Drug Class (NDA) to the US Food and Drug Administration (FDA) for avacincaptad pegol. This novel investigational drug is a complement C5 inhibitor being developed for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). The submission follows a rolling review process.
In November 2022, the European Commission granted marketing authorization for Ximluci, which is the third biosimilar of ranibizumab to receive approval in the European Union. The collaboration between STADA Arzneimittel and Xbrane Biopharma resulted in the development of Ximluci, and it is anticipated to be launched in the early months of 2023.

FAQs

Global Macular Degeneration Treatment Market size was valued at USD 16.7 billion in 2023 and is poised to grow from USD 18.12 billion in 2024 to USD 34.8 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032).

The global macular degeneration treatment market is highly competitive and characterized by the presence of several major players. These companies focus on developing innovative therapies and drugs to address the growing demand for effective treatments. Some of the key players in the market often engage in strategic collaborations, partnerships, and mergers and acquisitions to strengthen their market position and expand their product portfolios. Additionally, advancements in treatment and increasing research and development activities further intensify the competition in the market. The competitive landscape is driven by a constant drive for innovation, regulatory approvals, and the ability to provide cost-effective and efficient treatment options to patients with macular degeneration. 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'Novartis AG (Switzerland) ', 'Bayer AG (Germany) ', 'Pfizer Inc. (United States) ', 'Regeneron Pharmaceuticals Inc. (United States) ', 'AbbVie Inc. (United States) ', 'Santen Pharmaceutical Co., Ltd. (Japan) ', 'Bausch Health Companies Inc. (Canada) ', 'Amgen Inc. (United States) ', 'Biogen Inc. (United States) ', 'Samsung Bioepis (South Korea) ', 'PanOptica (United States) ', 'REGENXBIO Inc. (United States) ', 'Lineage Cell Therapeutics (United States) ', 'Ocugen Inc. (United States) ', 'Olix Pharmaceuticals Inc. (South Korea) ', 'ONL Therapeutics (United States) ', 'MeiraGTx (United States) ', 'OnPoint Vision Inc. (United States) ', 'Alcon (Switzerland)'

The aging population is a significant driver of the macular degeneration treatment market. Macular degeneration primarily affects individuals over the age of 50, and as the global population continues to age, the prevalence of this condition is expected to rise. According to the World Health Organization, the number of people aged 60 years and older is projected to double by 2050. This demographic shift is likely to increase the demand for effective treatments for macular degeneration.

Telemedicine and Remote Monitoring: The adoption of telemedicine and remote monitoring technologies has witnessed a significant surge in the macular degeneration treatment landscape. These technologies allow healthcare providers to remotely assess patients' vision and disease progression, reducing the need for frequent in-person visits. Remote monitoring enables timely intervention and better disease management while improving patient convenience and reducing healthcare costs. For instance, home-based visual acuity testing and smartphone-based imaging devices can aid in monitoring disease progression and treatment response remotely.

North America dominated the macular degeneration treatment market, owing to its robust healthcare infrastructure, increasing prevalence of age-related macular degeneration (AMD), and the presence of key market players. This region has emerged as a frontrunner in developing cutting-edge treatment options for macular degeneration, driving significant market growth. In the United States, pharmaceutical companies are revolutionizing the treatment landscape with the advent of anti-VEGF (vascular endothelial growth factor) therapies. These groundbreaking drugs, such as Lucentis and Eylea, have transformed the treatment paradigm by providing highly effective and minimally invasive solutions. Their widespread adoption has led to substantial market share gains for pharmaceutical giants operating in this region. Canada, another prominent player in North America, has witnessed significant advancements in macular degeneration treatment. The country boasts leading research institutions and ophthalmology centers that are at the forefront of developing innovative therapeutic approaches. Moreover, the Canadian government's focus on improving healthcare access and affordability has further bolstered the market. With the introduction of novel treatments, such as gene therapies and implantable devices, Canada has secured a substantial share in the global macular degeneration treatment market.